Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Biocon and Mylan Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S.

Posted On: 2019-12-02 23:52:47

This FDA-approved product, co-developed by Biocon Biologics and Mylan, was unanimously recommended by the FDA Oncologic Drugs Advisory Committee

Mylan to offer Ogivri in both the 420mg and 150mg strengths, increasing access to treatment for thousands of HER2-positive breast and gastric cancer patients

Biocon Ltd. (BSE code: 532523, NSE: BIOCON) and Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin® (trastuzumab). Ogivri is available in a 420mg multi-dose vial and a 150mg single-dose vial in order to provide patient dosing and treatment flexibility.

Ogivri was the first biosimilar trastuzumab approved by the U.S. Food and Drug Administration (FDA) and unanimously recommended by the FDA Oncologic Drugs Advisory Committee (ODAC). Ogivri is approved for all indications of Herceptin including for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma). Trastuzumab and biosimilar trastuzumab products contain a Boxed Warning for cardiomyopathy, infusion reactions, pulmonary toxicity and embryo-fetal toxicity.

Two supplemental Biologics License Applications were recently approved by the FDA, expanding the manufacturing capability for Ogivri, as well as Mylan and Biocon's first U.S. biosimilar, Fulphila®, a biosimilar to Neulasta®. Mylan and Biocon Biologics have sufficient manufacturing capacity to fulfil demand in the U.S. and global markets for both products.

Dr Christiane Hamacher, CEO, Biocon Biologics, said: "The U.S. launch of Ogivri, the biosimilar trastuzumab co-developed by Biocon Biologics and Mylan, marks a significant milestone in our biosimilars journey. It is an important endorsement of our science, development and manufacturing capabilities in the area of monoclonal antibodies. The introduction of both 420mg multi-use vials and 150mg single-use vials of a high quality biosimilar trastuzumab with robust long-term efficacy and safety data will offer greater choice and value to patients, prescribers and payors in the U.S. As a global frontrunner in biosimilars, Biocon Biologics is committed to fulfil unmet patient needs by providing greater affordability for enhanced patient access. We aspire to serve 5 million patients through our biosimilars portfolio and cross a revenue milestone of US$ 1bn by FY22.

"Ogivri is the second biosimilar from our partnered portfolio being commercialized by Mylan in the U.S. Last year, through the launch of Fulphila we helped in expanding patient access to biosimilar Pegfilgrastim," she added.

Mylan President Rajiv Malik commented: "As one of the largest suppliers of oncology medicines in the U.S., we are proud to offer Ogivri, biosimilar trastuzumab, in both the 420mg and 150mg strengths and help increase more affordable access to this important treatment option for breast and gastric cancer patients. With regulatory approval for our biosimilar trastuzumab in more than 80 countries worldwide, we are bringing vast global biosimilars experience to the U.S. and look forward to continuing our work with all stakeholders in the healthcare system to reduce costs, improve access and advance care. With Ogivri, Fulphila and our generic oncology portfolio, Mylan is uniquely positioned to provide a broad range of treatment options for oncology patients."

Malik continued, "Today's launch has been achieved through years of hard work, as a result of our successful collaboration with Biocon. Our early settlement and license with Roche to bring this product to market allows us to launch Ogivri without legal risk."

FDA approval of Ogivri was based on robust data demonstrating that Ogivri is highly similar to Herceptin and no clinically meaningful differences exist between the biosimilar product and Herceptin in terms of safety, purity and potency. Long-term results of the landmark HERITAGE study including overall survival data at 36 months were presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting.

Dr. Hope S. Rugo, professor of medicine at the University of California, San Francisco, and lead author of the HERITAGE study commented: "Trastuzumab-dkst (Ogivri) has many firsts to its credit. It was one of the first biosimilar oncology products to get a unanimous approval vote at an ODAC meeting, and it was the first biosimilar study to be published in the Journal of the American Medical Association. In this context, the HERITAGE study had a unique trial design that not only evaluated objective response rate at week 24 as its primary endpoint but also assessed key endpoints including progression-free survival rate and overall survival at 36 months. The concordant efficacy data across all three endpoints conclusively demonstrated that Ogivri was similar to Herceptin, and patients without progression now continue on Ogivri as maintenance therapy. We are pleased that patients with HER2-positive cancers now have an additional treatment option backed by robust safety and efficacy data, including long-term 36-month data. The worldwide introduction of this agent has already improved access to trastuzumab."

Ogivri is the second biosimilar to be offered by Mylan through the Mylan-Biocon Biologics partnership in the U.S. and the second FDA-approved biosimilar through this collaboration to support cancer patients. A full suite of patient services for Ogivri will be offered through the Mylan Advocate program. Mylan and Biocon launched the world's first biosimilar trastuzumab in India in 2014.

Today, Mylan has one of the largest and most diverse biosimilars portfolios, with 20 biosimilar and insulin analog products in development or on the market.

Shares of BIOCON LTD. was last trading in BSE at Rs.285.95 as compared to the previous close of Rs. 281.65. The total number of shares traded during the day was 399358 in over 6254 trades.

The stock hit an intraday high of Rs. 291.9 and intraday low of 281.95. The net turnover during the day was Rs. 114772369.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Blue Star wins the prestigious 'Golden Peacock Award for Corporate Ethics' for 2019

IndusInd Bank introduces its Wealth Management platform 'PIONEER' Banking

Hexaware strengthens its Leadership team

Godrej Properties launches Godrej RKS at RK Studios, Chembur, Mumbai

JK Agri Genetics Ltd board approves preferential issue to promoter group

Persistent Systems and ValidSoft deliver new Secure Digital Voice Authentication Capabilities for Banking and Credit Unions

Zensar Technologies Ltd Board approves interim dividend of Rs. 1

Sadhana Nitro Chem Ltd board to consider stock split

Zee Media Corporation Ltd announces Q3 FY2020 results

Floor price of KEI Industries Ltd's QIP fixed as Rs. 518.14

Sharika Enterprises Ltd bags award at Elecrama 2020

S P Apparels Ltd to sell retail division for Rs. 81 crores

Olectra Greentech Ltd group receives LOA for deployment of 555 electric buses

HFCL Ltd commissons greenfield optical fibre facility at Telangana

SAEINDIA and Mahindra inaugurates the 13th edition of BAJA SAEINDIA 2020, today at Pithampur

IndiGo announces daily direct flights between Mumbai and Chengdu

Tata Motors partners with what3words: Redefining navigation with just 3 words

SBI Funds Management Private Limited announces Compliance with GIPS®

DoT asks GAIL India Ltd to pay Rs. 1,83,076 crore

JK Agri Genetics Ltd Q3 loss at Rs. 3.78 crore

Indiabulls Ventures Ltd consolidated Q3 PAT drops to Rs. 101.39 crores

Indo Thai Securities Ltd posts net profit of Rs. 0.61 crore in Q3

Pioneer Distilleries Ltd Q3 loss at Rs. 12.78 crore

NELCO Ltd Q3 consolidated net profit at Rs. 3.65 crore

BIOCON Ltd Q3 consolidated PAT slips to Rs. 202.8 crore

Zensar Technologies Ltd reports consolidated PAT of Rs. 39.53 crores in Q3

Kokuyo Camlin Ltd Q3 loss at Rs. 2.24 crore

Automotive Stampings & Assemblies Ltd Q3 PAT at Rs. 2.97 crore

Rane Brake Lining Ltd reports net profit of Rs. 10.23 crore in Q3

Rane Brake Lining Ltd Board approves interim dividend of Rs. 6

South India Paper Mills Ltd posts PAT of Rs. 4.24 crore in Q3

Mitshi India to raise capital via preferential allotment of shares for business expansion

Automobile Corporation of Goa Ltd board declares interim dividend of Rs. 5 for FY2019-20

Subex Ltd settles pending litigations with ex-directors

Cholamandalam Investment and Finance Company Ltd Q3 consolidated net profit higher at Rs. 389.16 crores

Automobile Corporation of Goa Ltd posts loss of Rs. 1.41 crore in Q3

Bayer Cropscience Ltd calls for board meeting on Feb 3, 2020

EIH Associated Hotels Ltd Q3 net profit at Rs. 20.37 crores

GHCL Ltd Board approves Buy-Back of Equity Shares

HDFC Life Insurance Company Ltd reports consolidated PAT of Rs. 251.09 crores in Q3

PNB Housing Finance Ltd Q3 consolidated net profit declines to Rs. 237.02 crores

APAR Industries Ltd consolidated Q3 net profit at Rs. 36.67 crore

NCLT approves IPCA Laboratories Ltd's resolution plan for Noble Explochem Ltd

Nippon Life India Asset Management Ltd board approves interim dividend of Rs. 3

GHCL Ltd Q3 FY20 consolidated net profit slips to Rs. 96.91 crores

Nippon Life India Asset Management Ltd consolidated Q3 PAT up at Rs. 149.32 crores

JM Financial Ltd reports consolidated profit of Rs. 157.54 crores in Q3

KEC International wins New Orders of Rs. 1,255 crore

GE T&D India wins a SCADA & ADMS project from Jammu & Kashmir Power Development Department to deliver 24/7 power availability

Dishman Carbogen Amcis Ltd Q3 consolidated PAT drops QoQ, YoY







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019